Your browser doesn't support javascript.
loading
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard, John P; Trneny, Marek; Izutsu, Koji; Fowler, Nathan H; Hong, Xiaonan; Zhu, Jun; Zhang, Huilai; Offner, Fritz; Scheliga, Adriana; Nowakowski, Grzegorz S; Pinto, Antonio; Re, Francesca; Fogliatto, Laura Maria; Scheinberg, Phillip; Flinn, Ian W; Moreira, Claudia; Cabeçadas, José; Liu, David; Kalambakas, Stacey; Fustier, Pierre; Wu, Chengqing; Gribben, John G.
Afiliación
  • Leonard JP; 1 Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY.
  • Trneny M; 2 Charles University, General Hospital, Prague, Czech Republic.
  • Izutsu K; 3 National Cancer Center Hospital, Tokyo, Japan.
  • Fowler NH; 4 The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hong X; 5 Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
  • Zhu J; 6 Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
  • Zhang H; 7 Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.
  • Offner F; 8 Ghent University Hospital, Gent, Belgium.
  • Scheliga A; 9 Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
  • Nowakowski GS; 10 Mayo Clinic, Rochester, MN.
  • Pinto A; 11 Istituto Nazionale Tumori IRCCS - Fondazione Pascale, Naples, Italy.
  • Re F; 12 Azienda Ospedaliero Universitaria di Parma, Parma, Italy.
  • Fogliatto LM; 13 Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Scheinberg P; 14 Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
  • Flinn IW; 15 Sarah Cannon Research Institute, Nashville, TN.
  • Moreira C; 16 Instituto Português de Oncologia do Porto Francisco Gentil Epe, Porto, Portugal.
  • Cabeçadas J; 17 Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
  • Liu D; 18 Celgene Corporation, Summit, NJ.
  • Kalambakas S; 18 Celgene Corporation, Summit, NJ.
  • Fustier P; 19 Celgene International, Boudry, Switzerland.
  • Wu C; 18 Celgene Corporation, Summit, NJ.
  • Gribben JG; 20 Barts Cancer Institute, London, United Kingdom.
J Clin Oncol ; 37(14): 1188-1199, 2019 05 10.
Article en En | MEDLINE | ID: mdl-30897038
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Folicular / Linfoma de Células B de la Zona Marginal / Rituximab Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Folicular / Linfoma de Células B de la Zona Marginal / Rituximab Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Oncol Año: 2019 Tipo del documento: Article